# Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

> **NCT02251990** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 489 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Grazoprevir/Elbasvir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02251990
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-28
- **Primary completion:** 2016-09-27
- **Final completion:** 2017-04-10
- **Target enrollment:** 489 (ACTUAL)
- **Last updated:** 2019-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251990, "Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02251990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*